Stivarga (regorafenib) — United Healthcare
Glioblastoma
Initial criteria
- Diagnosis of recurrent or progressive glioblastoma
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Stivarga therapy
Approval duration
12 months